Is Actemra approved for giant cell arteritis (GCA)?
Yes, Actemra (tocilizumab) is FDA-approved for treating giant cell arteritis in adults. The approval came in 2017 as the first new treatment for GCA in over 50 years, targeting adults who have not responded well enough to corticosteroids alone.[1]
How does Actemra work for GCA?
Actemra is an interleukin-6 (IL-6) receptor inhibitor that reduces inflammation by blocking IL-6 signaling, a key driver in GCA's vascular damage. It's given as a subcutaneous injection weekly or every other week, often alongside a tapering steroid regimen.[1]
What do clinical trials show?
The phase 3 GiACTA trial tested Actemra against placebo in 251 GCA patients. Those on weekly subcutaneous Actemra plus 26-week prednisone taper achieved sustained remission in 56% of cases at one year, compared to 14% on placebo plus longer taper. It also cut cumulative steroid doses by 52%.[2]
Who makes Actemra and what's the pricing?
Genentech (a Roche subsidiary) manufactures Actemra. List prices for subcutaneous doses run about $1,800-$2,000 per vial, with annual costs exceeding $50,000 depending on weight and regimen; patient assistance programs can lower this.[3]
When does Actemra's patent expire for GCA?
Core patents on tocilizumab expired in the US around 2016-2017, but formulation and method-of-use patents extend exclusivity. DrugPatentWatch lists key US patents like 8,420,089 (expires 2028) covering subcutaneous use, with ongoing litigation from biosimilar challengers like Fresenius Kabi.[4]
What are common side effects in GCA patients?
In GiACTA, serious infections occurred in 9% of Actemra patients vs. 4% placebo; other risks include elevated liver enzymes, cholesterol changes, and GI perforations. Patients on steroids face amplified infection risks—monitoring is standard.[1][2]
How does it compare to steroids alone or other options?
Steroids remain first-line for GCA but cause long-term issues like osteoporosis. Actemra allows faster, safer tapering. Methotrexate is sometimes added but less effective per trials. No direct head-to-head with emerging IL-6 inhibitors like sarilumab (Kevzara), approved later for GCA.[1]
Sources
[1]: FDA Label for Actemra
[2]: NEJM GiACTA Trial
[3]: Genentech Pricing Info
[4]: DrugPatentWatch - Tocilizumab Patents